Confined or spread disease-Spread with distant metastasis Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread with distant metastasis Posts on Medivizor

FOLFOXIRI plus bevacizumab improves survival of patients with advanced colorectal cancer

FOLFOXIRI plus bevacizumab improves survival of patients with advanced colorectal cancer

Posted by on Sep 19, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients. Some background Around 20% of patients present with advanced CRC at diagnosis....

Read More

Does neratinib plus capecitabine benefit patients with heavily treated HER2-positive metastatic breast cancer?

Does neratinib plus capecitabine benefit patients with heavily treated HER2-positive metastatic breast cancer?

Posted by on Aug 20, 2020 in Breast cancer | 0 comments

In a nutshell This trial compared the effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) in treating metastatic breast cancer compared to lapatinib (Tykerb) plus capecitabine in patients who have received 2 or more treatment lines. The authors found that neratinib plus capecitabine (N+C) resulted...

Read More

Searching for patients with advanced breast cancer to trial an experimental drug combination

Searching for patients with advanced breast cancer to trial an experimental drug combination

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...

Read More

Panitumumab and capecitabine improves the outcomes of older patients with advanced colorectal cancer

Panitumumab and capecitabine improves the outcomes of older patients with advanced colorectal cancer

Posted by on Jul 26, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of panitumumab (Vectibix) and capecitabine (Xeloda) combination to treat older patients with advanced colorectal cancer (CRC). Researchers suggested that this combination is a good and safe treatment for older patients with CRC. Some background CRC is a common cancer worldwide. CRC patients are...

Read More

The outcomes of trastuzumab emtansine in patients with brain metastasis from HER2-positive breast cancer

The outcomes of trastuzumab emtansine in patients with brain metastasis from HER2-positive breast cancer

Posted by on Jul 19, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the effects of trastuzumab emtansine (T-DM1; Kadcyla) to treat patients with brain metastasis (BM) from HER2-positive metastatic breast cancer (mBC). The main finding was that T-DM1 was safe and effective in such patients. Some background HER-2 positive mBC cells have an excess of the HER-2 protein. Such cancers...

Read More

Cetuximab combined with chemotherapy improves the outcomes of patients with advanced colorectal cancer

Cetuximab combined with chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jul 11, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of cetuximab (Erbitux) in combination with chemotherapy for the treatment of advanced colorectal cancer (CRC). Researchers suggested that this combined treatment improves the outcomes of patients with CRC. Some background CRC is one of the most common cancers worldwide. Around 15 to 25% of...

Read More

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jul 1, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared two different chemotherapy treatments in metastatic colorectal cancer (mCRC; spread to other parts of the body). Researchers suggested that 24-hour infused irinotecan (Camptosar) plus oral S-1 (Teysuno) chemotherapy and bevacizumab (Avastin) is well tolerated and associated with improved outcomes. Some background...

Read More

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Posted by on Jun 28, 2020 in Melanoma | 0 comments

In a nutshell The study monitored the occurrence of possible immune-related side effects (irSEs) in patients with advanced melanoma under single and combination therapy of ipilimumab (I; Yervoy), nivolumab (N; Opdivo), and pembrolizumab (P; Keytruda). The authors found that combination therapy increases the frequency of irSEs. Some background...

Read More

Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain

Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain

Posted by on Jun 14, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases (BM) with tucatinib (Tukysa) plus trastuzumab (Herceptin) and capecitabine (Xeloda). This study found that this treatment reduces the risk of cancer worsening in these...

Read More

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

Posted by on May 24, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) treatment in older patients with colorectal cancer (CRC). Researchers suggested that this treatment has similar effects in younger and older patients. Some background CRC is the third most common cancer worldwide. More than half are diagnosed in patients older...

Read More

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Posted by on May 17, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of bevacizumab biosimilar (BE1040V) to the reference drug (Avastin) in the treatment of patients with metastatic colorectal cancer (mCRC). Researchers suggested that the effectiveness and safety of the biosimilar were similar to the reference drug bevacizumab. Some...

Read More